GlassScriptPhysician profile
Aamir Rasheed
NPI 1568547933
$197,247.98
in general payments reported to CMS, 2019-2025
68 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $32K · 2021: $26K · 2022: $36K · 2023: $25K · 2024: $9,659 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $11K · Consulting Fee: $3,600 · Travel and Lodging: $1,071 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,844.25 |
| Food and Beverage | $10,559.74 |
| Consulting Fee | $3,600.00 |
| Travel and Lodging | $1,071.00 |
| Education | $293.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $90,346.88 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $41,183.71 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $17,152.17 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Allergan, INC. | $16,549.53 | 2019-2022 | |
| Amgen INC. | $11,364.77 | 2019-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $8,068.73 | 2019-2025 | |
| Livanova USA, INC. | $2,915.60 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $849.85 | 2020-2025 | Infinity |
| Celgene Corporation | $674.70 | 2021-2025 | Zeposia |
| Genzyme Corporation | $653.16 | 2019-2025 | |
| Biogen, INC. | $639.52 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Pfizer INC. | $572.25 | 2019-2025 | |
| Sk Life Science, INC. | $477.85 | 2020-2025 | |
| Mdd US Operations, LLC | $458.90 | 2019-2024 | Gocovri, Apokyn, Myobloc |
| Ucb, INC. | $344.32 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.